Citadel Advisors’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-28,616
| Closed | -$103K | – | 6026 |
|
|
2024
Q4 | $103K | Sell |
28,616
-5,481
| -16% | -$19.7K | ﹤0.01% | 5182 |
|
|
2024
Q3 | $194K | Sell |
34,097
-339,560
| -91% | -$1.94M | ﹤0.01% | 4647 |
|
|
2024
Q2 | $1.73M | Buy |
373,657
+39,139
| +12% | +$181K | ﹤0.01% | 2576 |
|
|
2024
Q1 | $2.73M | Buy |
334,518
+287,304
| +609% | +$2.35M | ﹤0.01% | 2232 |
|
|
2023
Q4 | $267K | Sell |
47,214
-346,728
| -88% | -$1.96M | ﹤0.01% | 4338 |
|
|
2023
Q3 | $733K | Sell |
393,942
-275,540
| -41% | -$513K | ﹤0.01% | 3371 |
|
|
2023
Q2 | $1.84M | Buy |
669,482
+142,328
| +27% | +$391K | ﹤0.01% | 2488 |
|
|
2023
Q1 | $1.66M | Buy |
527,154
+147,654
| +39% | +$464K | ﹤0.01% | 2691 |
|
|
2022
Q4 | $2.24M | Buy |
379,500
+249,713
| +192% | +$1.47M | ﹤0.01% | 2474 |
|
|
2022
Q3 | $1.14M | Buy |
129,787
+101,836
| +364% | +$893K | ﹤0.01% | 3288 |
|
|
2022
Q2 | $211K | Sell |
27,951
-80,278
| -74% | -$606K | ﹤0.01% | 4960 |
|
|
2022
Q1 | $2.63M | Sell |
108,229
-53,727
| -33% | -$1.3M | ﹤0.01% | 2712 |
|
|
2021
Q4 | $5.22M | Buy |
161,956
+121,621
| +302% | +$3.92M | ﹤0.01% | 2065 |
|
|
2021
Q3 | $1.8M | Sell |
40,335
-70,443
| -64% | -$3.15M | ﹤0.01% | 3135 |
|
|
2021
Q2 | $4.19M | Buy |
110,778
+90,527
| +447% | +$3.43M | ﹤0.01% | 2360 |
|
|
2021
Q1 | $749K | Sell |
20,251
-83,622
| -81% | -$3.09M | ﹤0.01% | 4211 |
|
|
2020
Q4 | $3.44M | Buy |
+103,873
| New | +$3.44M | ﹤0.01% | 2081 |
|